|Bid||86.65 x 900|
|Ask||88.68 x 1100|
|Day's Range||88.13 - 88.32|
|52 Week Range||60.27 - 146.79|
|Beta (3Y Monthly)||2.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||120.67|
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNYView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for ALNY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ALNY had net inflows of $3.63 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Alnylam (ALNY) submits a CTA application to The Medicines and Healthcare products Regulatory Agency in the United Kingdom for ALN-AGT for the treatment of uncontrolled hypertension.
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom to initiate a Phase 1 study of ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension in high unmet need populations, including patients with resistant or refractory hypertension, chronic kidney disease or heart failure. The Company plans to initiate a Phase 1 study in mid-2019, upon obtaining MHRA approval. “We are excited to expand our efforts in the cardiovascular disease setting in pursuit of a novel approach to treat hypertension, particularly given that hypertensive disorders are the leading preventable cause of death in modern society.
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Cowen & Company 39th Annual Health Care Conference on Wednesday, March 13, 2019 at 11:20 am ET at the Marriott Copley Place in Boston. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform.
Alnylam (ALNY) reports positive phase III data on investigational candidate, givosiran. Despite the results, its shares slipped almost 4% on investors' concern regarding adverse events.
Alnylam Pharmaceuticals stock slipped Wednesday as investors questioned the safety of its rare-disease drug, dubbed givosiran, in a late-stage test of patients with acute hepatic porphyria.
Alnylam Pharmaceuticals Inc's late-stage trial data on its new gene silencing drug cast doubt on its safety, even as results revealed its effectiveness in treating a rare, painful disease. Alnylam said the drug, givosiran, met the main goal of reducing the yearly number of attacks in patients with acute intermittent porphyria (AIP) - a disease that affects the liver and causes debilitating attacks that render most disabled. Givosiran's efficacy profile looks robust but its safety profile is materially worse than expected, SVB Leerink analyst Mani Foroohar said in a note.
Shares of Alnylam Pharmaceuticals Inc. fell 7.5% in premarket trade Wednesday after the company announced results of a Phase 3 study of givosiran, an RNA interference therapy for the treatment of acute hepatic porphyria, a family of rare genetic diseases that can cause potentially life-threatening attacks of severe abdominal pain, weakness and fatigue. The study met its primary endpoint -- reducing the yearly rate of porphyria attacks compared with placebo -- and hit five of nine secondary endpoints. But investors seemed spooked by the high percentage of serious adverse events reported by patients on givosiran compared with those on a placebo: 20.8% of those on givosiran reported serious adverse events compared to 8.7% of patients on placebo, though the difference in overall adverse events was not as stark, with 89.6% of patients on the drug reporting adverse events of any kind compared with 80.4% of patients on placebo. One patient discontinued treatment after seeing the amount of the liver enzyme alanine aminotransferase increase to more than eight times the normal number. Acute hepatic porphyria happens when a genetic defect leads to issues with one of the enzymes responsible for making heme in the liver. That causes a build-up of heme precursors, which are toxic to the body. Alnylam's givosiran targets an enzyme in the heme-making pathway called aminolevulinic acid synthase 1 (ALAS1). Alnylam said full study results will be presented in April and the company plans to submit a new drug application in mid-2019. Shares of Alnylam have gained 10.8% in the past 3 months, while the S&P 500 has gained 3.5%.
The company announced Wednesday that its drug givosiran met its primary endpoints in a Phase 3 trial.
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP), met its primary efficacy endpoint and the majority of secondary endpoints. Specifically, givosiran met the primary endpoint of reduction in the annualized rate of composite porphyria attacks relative to placebo (p less than 0.00000001) and achieved statistically significant results for five of nine secondary endpoints (p less than 0.0001), with a safety and tolerability profile that the Company believes is encouraging, especially in this high unmet disease.
The Medicines Company (MDCO) suffers a wider-than-expected loss in Q4. At the same time, the company fails to generate revenues.
– Competitive Grants Program Recognizes New Projects that Impact the ATTR Amyloidosis and Acute Hepatic Porphyria Patient Communities –
The company's path forward is uncertain after FDA officials wrote in an advisory committee briefing document Friday that Karyopharm's drug was linked to "significant toxicity" and potentially lowered cancer patients' survival rates.
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. Warning! GuruFocus has detected 3 Warning Signs with ALNY. For the last quarter Alnylam Pharmaceuticals Inc reported a revenue of $21.0 million, compared with the revenue of $37.92 million during the same period a year ago.
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 7.) Array Biopharma Inc (NASDAQ: ARRY ) Down In The Dumps (Biotech ...